Numbers

Codex View

The Numbers

CI trades here because the market is treating it as a post-Medicare portfolio reset with a PBM overhang, not as a company with broken cash generation. The clean rerating metric is Evernorth-backed adjusted EPS growth, because GAAP earnings are still distorted by investment losses, sale accounting, and amortization.

Valuation Snapshot

The stock is back near its 2023 range even after adjusted EPS climbed close to $30 and free cash flow yield moved into double digits. That is the core setup: the market is discounting mix reset and PBM durability, not current cash generation.

Earnings Power

Revenue kept climbing as Evernorth became a larger part of the mix, but GAAP EPS became a bad anchor because VillageMD impairments, the Medicare divestiture, and amortization swamped the core trend. Adjusted EPS rose every year from FY2021 through FY2025, which is the earnings stream the market is really capitalizing.

Quarterly revenue kept stair-stepping higher through 2025, so the top-line damage from the Medicare exit is not showing up in the consolidated run-rate. The confidence break was the FY2024 Q4 miss; since then results have reverted to small beats, which is what the stock needs to keep rebuilding trust.

Cash Generation

Cash conversion is the strongest part of the CI case. Absolute free cash flow has stayed in an $8-10B band while buybacks cut diluted shares by more than one-fifth since FY2021, so per-share cash economics improved materially even without a straight-line FCF ramp.

Balance Sheet

This is not a stressed balance sheet for a company producing this much cash, but it is also not a clean book-value story. Goodwill and intangibles still sit well above common equity, so the downside case is more about execution and mix deterioration than near-term refinancing risk.

Critical Chart

The chart explains the stock. Evernorth is now the earnings engine and kept growing through FY2025, while Cigna Healthcare stepped down as the Medicare businesses left the portfolio. If Evernorth growth holds despite rebate-free investment and PBM policy pressure, today’s multiple looks too low; if it stalls, the discount probably persists.

Peer Valuation

CI screens as the cheapest name in the group on forward earnings despite ROE that holds up well against ELV, UNH, and MOH. That discount looks more like a skepticism tax on PBM durability and portfolio transition than a judgment that current earnings power is weak.

The numbers confirm that CI is still a high-cash, shareholder-friendly compounder at the per-share level. They contradict any view that reported GAAP volatility equals core earnings deterioration, because adjusted EPS, Evernorth profit, and free cash flow stayed resilient. Next quarter, watch Evernorth profit growth, cash conversion versus adjusted earnings, and whether the post-Medicare Cigna Healthcare base stabilizes without a new confidence break.

Claude View

The Numbers

Cigna Group trades at $278, a 12.5x trailing P/E and 8.9x forward P/E – one of the cheapest multiples in managed care. The stock sits 19% below its 52-week high of $343 and 22% below the consensus analyst target of $339. The single metric most likely to rerate CI is its medical cost ratio trajectory: Evernorth Services provides earnings stability, but the market is pricing in MLR risk from the broader managed care sector selloff. Adjusted EPS grew from $20.47 in FY2021 to $29.85 in FY2025, a 10% CAGR, while the share count shrank 12% over the same period.

Stock Price (Last 24 Months)

CI peaked near $365 in September 2024 before the managed care sector de-rating took hold. The stock dropped sharply in January 2025 after a Q4 2024 EPS miss (-15% surprise), then drifted lower through late 2025 as sector-wide MLR concerns persisted. The stock has traded in a $240-$340 range for the past 12 months and currently sits near the lower end, reflecting ongoing uncertainty about Medicaid redeterminations and Medicare Advantage rate adequacy.

Revenue & Earnings Power

Revenue grew from $160B to $275B over five years, a 71% increase driven heavily by Evernorth's pharmacy benefits and specialty pharmacy volumes (low-margin, high-throughput). EBITDA grew only 12% over the same period ($10.4B to $11.6B), confirming that top-line growth is mostly pass-through pharmacy revenue. Operating income has plateaued around $9B, and net income was distorted in FY2024 by a VillageMD-related impairment.

Quarterly revenue has climbed steadily from $57B to $72B, but operating income oscillates between $2.0B and $2.6B per quarter with no clear upward trend. Q4 quarters are consistently weaker on operating income due to seasonal healthcare utilization patterns and year-end reserve adjustments.

EPS Growth & Earnings Surprises

Adjusted EPS has compounded at ~10% annually from FY2019 to FY2025, driven by a combination of operating leverage and aggressive share repurchases. This is the metric management optimizes around, and it has been remarkably consistent even as GAAP net income has been volatile.

Cash Generation

Cigna generates $8-10B in annual FCF on ~$275B of revenue – a thin 3.1% FCF margin, typical for managed care. The critical metric is FCF yield: at 11.3% on a $74B market cap, CI converts operating earnings to cash far more efficiently than GAAP net income suggests. FCF consistently exceeds GAAP net income because D&A ($2.8B) outstrips capex ($1.2B), and intangible amortization from the Express Scripts acquisition is a non-cash drag on GAAP earnings.

Capital Allocation & Share Count

Cigna has retired nearly 23% of its float since FY2021, buying back ~78M shares. At the current price of $278, FCF per share is $31.80 – meaning investors are paying 8.7x FCF per share. This is the most compelling metric in the CI story: the company is systematically shrinking the denominator while maintaining a ~$9B annual FCF run rate.

Balance Sheet & Leverage

The balance sheet is acquisition-heavy: $44.9B in goodwill (28% of total assets) is almost entirely from the 2018 Express Scripts deal. Total debt of $31.5B is manageable at 2.7x net debt/EBITDA, and the company has been deleveraging steadily from 3.4x at close of the Express Scripts transaction. Interest expense of $1.4B is well-covered by $9.1B in operating income.

Margin Profile

Gross margins have compressed from 15.1% to 9.5% as pharmacy pass-through revenue (Evernorth) has become a larger share of the mix. This is largely an optical effect – the high-volume, low-margin pharmacy revenue inflates the denominator while the higher-margin Cigna Healthcare segment maintains more stable economics. Operating margin has compressed modestly from 5.1% to 3.3%. The true measure of profitability is adjusted EPS and FCF, not GAAP margins.

Peer Comparison

CI trades at a significant discount to UNH (8.9x vs 15.8x forward P/E) despite posting more consistent earnings growth. ELV is the closest comp at 11.8x forward, and CVS at 10.3x, but both carry operational issues (ELV's Medicaid margin pressure, CVS's restructuring overhang). The managed care sector is broadly de-rated from 2023 peaks, but CI's discount to the group reflects (1) the Express Scripts integration complexity, (2) lower margins optically diluted by pharmacy pass-through, and (3) modest ongoing concerns about specialty pharmacy pricing regulation.

CI sits in the lower-left quadrant: low valuation, moderate growth. This positions it as a value play rather than a growth compounder. UNH commands the premium thanks to Optum's services diversification. HUM and MOH trade at higher multiples despite negative recent EPS growth, reflecting either market expectations of mean reversion or merger speculation.

Critical Chart: Adjusted EPS vs Share Price

Summary

The numbers confirm Cigna is a cash flow machine: $8-9B in annual FCF, a 23% share count reduction over four years, and a remarkably consistent adjusted EPS CAGR of ~10%. The numbers contradict the market's implied thesis of earnings deterioration – FY2025 adjusted EPS of $29.85 was an all-time high, and all four quarters beat estimates after the Q4 2024 miss. What must be watched next quarter: (1) medical cost ratio in the Cigna Healthcare segment, (2) Evernorth specialty pharmacy volume trends as biosimilar adoption accelerates, and (3) whether the buyback pace accelerates at these lower valuations to further compress the share count.